secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001493152-24-044741
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte reports Q3 loss of $13.5M; GraftAssure signed 2% US, 9% German transplant volumes
--------------------------------------------------------------------------------

- Q3 revenue $115K from pharma services; loss from operations $13.5M ($0.98/sh); non-GAAP loss $5.6M.
- Cash end Q3 $5.1M; raised $10.2M gross ($9.4M net) in Oct. private placement at $2.948/sh, 3.46M shares.
- GraftAssure signed centers: ~9% German, ~2% US transplant volumes; on track for 20 centers by end of 2025.
- FDA pre-sub (Q-sub) submitted for VitaGraft+ IVD; meeting scheduled early Dec.; six hospitals interested in clinical study.
- Operating expenses (excl. non-cash) rose ~13% sequentially to $13.6M, driven by R&D and sales/marketing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224044741/0001493152-24-044741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224044741/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer